Need Help?
Tutorial FAQ
Glossary Contact Us


User Name




^Return to Top^


^Return to Top^


Cancer Histopathology
Identifies whether cancer-related characteristics (e.g., grade, stage, Gleason score, etc.) are included in the prognostic estimates.

Cancer Site
The body organ or system where cancer originates; the anatomical site of origin.

Cancer Specifc Overall Survival
Cancer specific overall survival is a net survival measure representing survival of a specified cause of death in the absence of other causes of death. Estimates are calculated by specifying the cause of death. Individuals who die of causes other than those specified are considered to be censored.

Clinical Response
The clinical response to treatment is an important indicator of the therapeutic effect of anticancer agents. Its value and interpretation has to be carefully considered within the context that it is used. In daily practice, response assessment is combined with other indicators of the patient's condition to contribute to the decision-making process. In clinical trials, it is widely used to identify and quantify the anti-tumour activity of new agents.

Colorectal Cancer Sites
colon, rectum, colorectal, cecum, hepatic flexure, splenic flexure, sigmoid colon, large intestine, rectosigmoid, anus, anal cavity.

^Return to Top^


Data Source
Describes the data that was used to develop the prognostic algorithm.

^Return to Top^


Endocrine Cancer Sites
adrenal, thyroid, other endocrine

^Return to Top^


Lists the funding sources that supported the development of the tool as disclosed on the tool's website.

^Return to Top^


Gynecologic Cancer Sites
ovarian, endometrial, cervix, uterus, ovary, vagina, vulva, other female genital organs

^Return to Top^


Head and Neck Cancer Sites
lung, mesothelioma, bronchus, pleura, trachea, mediastinum

Hemtologic Cancer Sites
lymphoma, myeloma, leukemia, hodgkins lymphoma disease/nodal, non-hodgkins lymphoma, multiple myeloma, acute lymphcyric leukemia, chronic lymphocyric leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute monocyric leukemia, chronic monocyric leukemia, other acute leukemias, other chronic leukemias

^Return to Top^


Impact of Therapy
Defines if the tool takes into account the impact of cancer therapy on outcomes.

Input Variables
Defines the list variables that are taken into account for the calculation of prognosis.

^Return to Top^


Last Updated Tool Abstraction
The date when the information was abstracted on the tool by our research team.

Last Updated Tool Website
The date indicated on the website of the last time the tool was updated.

^Return to Top^


Defines the different modalities the tool is available in (e.g., web-based, smartphone app, etc.)

^Return to Top^


Nervous System Cancer Sites
brain, other nervous system

Non-Cancer Related Survival
Non-cancer related survivalt denotes the chances of death due to conditions (or causes) other than cancer at a particular point of time. It takes care to exclude death due to cancer.

^Return to Top^


Other Gastrointestinal Cancer Sites
gastric, esophageal, pancreas, gallbladder, stomach, small intestine, liver, bile duct, other biliary, retroperitoneum, peritoneum, omentum, appendix

Other Genitourinary Cancer Sites
bladder, kidney/renal cell, penile, testis, other male genital organs, ureter, other urinary organs

Output Format
Describes what type of outputs are generated by the tool (e.g., numerical, varoius graphical formats)

Output Sharing
Lists the ways in which results from the tool can be shared with the end-user.

Output Variables
Provides a list of variables calculated by the tool for prognosis.

^Return to Top^


Patient Demographics
Defines whether the patient's demgraphic characteristics (e.g., age, gender, marital status) are taken into account when caluclating prognosis.

Patient Health Status
Defines whether the patient's health status are taken into account when caluclating prognosis.

Patient Modifiable Risk Factors
Defines whether the patient's modifiable risk factors (e.g., smoking status, obesity, etc.) are taken into account when caluclating prognosis.

Patient User
Defines if patients are recommended users of the tool as described by the tool's website.

Prognostic Tools
Decision aids that use an algorithm to calcaluate likely outcomes based on the characteristics of an individual.

Progression-Free Survival
Progression free survival is defined as the amount of time during and after treatment in which a cancer does not grow. (ref 1) Progression-free survival is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a predefined endpoint, there are many factors that can influence the exact moment of when disease progression is recorded. (ref 2)

^Return to Top^


Soft Tissue
bones and joints, Kaposi sarcoma, soft tissue sarcoma, uterine leimyosarcoma.

^Return to Top^


Thoracic Cancer Sites
lung, mesothelioma, bronchus, pleura, trachea, mediastinum

^Return to Top^


User Ratings
User ratings are calculated based on the average of how each tool is rated by the number of raters. Users can rate tools by registering and logging into the site.

^Return to Top^


Indicates whether the algorithm used by the tool has been validated as reported on the tool's website.

^Return to Top^